Charles River Laboratories
A global contract research organization providing drug discovery, preclinical, laboratory, and manufacturing support services.
Last updated September 23, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Charles River Laboratories International, Inc. is a United States-based contract research organization serving pharmaceutical, biotechnology, medical-device, government, and academic customers. Its work supports the development of medicines, vaccines, biologics, and medical technologies from early discovery through preclinical testing and selected clinical and manufacturing activities. The company is headquartered in Wilmington, Massachusetts, and is publicly traded on the New York Stock Exchange under the symbol CRL. The business began in 1947 when veterinarian Henry Foster established a small laboratory in the Boston area and supplied researchers with laboratory animals. Its name reflects its early location overlooking Boston's Charles River. The company relocated its headquarters to Wilmington in 1955 and began international expansion in 1966 with an animal-production facility in France. Over time, it developed from a supplier of research animals into a diversified scientific-services organization. Charles River's portfolio includes research models, laboratory-animal management, genetic monitoring, in vitro and in vivo pharmacology, toxicology, safety assessment, microbial and endotoxin testing, bioanalytical services, and support for biologics and cell- and gene-therapy development. Its laboratories produce data used by sponsors in regulatory submissions and development decisions, including work relevant to agencies such as the U.S. Food and Drug Administration. The company also provides manufacturing-related services for advanced therapies and other biopharmaceutical programs. Corporate development has been central to the brand's expansion. The company acquired or integrated businesses involved in avian services, endotoxin testing, clinical research, preclinical research, drug discovery, antibody discovery, cell and gene therapy, and contract development and manufacturing. The 2003 merger with Inveresk strengthened its clinical and preclinical capabilities, while later acquisitions such as BioFocus, Argenta, MPI Research, Citoxlab, HemaCare, Cognate BioServices, and Vigene broadened the organization beyond traditional laboratory-animal and toxicology services. Charles River is regarded as one of the world's largest CROs and, according to the supplied reference material, employed more than 20,000 people worldwide as of 2024. Its competitive positioning rests on combining research models, specialized testing, scientific expertise, global laboratory capacity, and regulatory-supporting documentation in a single service platform. At the same time, its activities involving laboratory animals, including rodents, dogs, nonhuman primates, and horseshoe crabs, have attracted scrutiny from animal-welfare groups and have generated regulatory and public-policy attention. The company has promoted animal-care initiatives, including its Humane Care Imperative, while continuing to operate in research areas where animal use remains part of many accepted development and testing methods.
History
Charles River Laboratories was established in 1947 by Henry Foster, a veterinarian who purchased about one thousand rat cages from a Virginia farm and created a small laboratory near Boston. The early enterprise supplied laboratory animals to researchers and developed a business model based on providing standardized research resources to institutions conducting biomedical studies. In 1955, the company moved its headquarters to Wilmington, Massachusetts, where it remains based. The organization became international in 1966 after opening an animal-production facility in France. Its service offering gradually expanded beyond animal supply. In 1981, Charles River introduced what the reference material describes as the first commercial comprehensive genetic-monitoring program, helping researchers assess the genetic integrity and health status of laboratory colonies. In 1984, Bausch & Lomb acquired the company. Charles River also purchased Specific Pathogen Antigen Free Avian Services and serologic diagnostic operations associated with Merck, Sharp & Dohme during this period. The company entered transgenic-animal work in 1988, when it began producing transgenic mice and rats. During the 1990s it expanded into in vitro endotoxin testing. Jim Foster later bought the business back from Bausch & Lomb, after which Charles River returned to independent growth and eventually became a public company listed on the New York Stock Exchange. Acquisitions became a major growth mechanism from the 1990s onward. Endosafe and Sierra Biomedical were acquired between 1996 and 2000. In 2003, Charles River merged with Inveresk, a United Kingdom research company specializing in clinical research and preclinical testing. The combination strengthened the company's ability to support programs beyond animal models and laboratory testing. Charles River subsequently sold its Edinburgh Clinical Services Division to Quotient Bioresearch in late 2009. From 2008 through 2013, the company added NewLab Bioquality, MIR Preclinical Services, Piedmont Research Center, Cerebricon, Accugenix, and Vital River. These transactions expanded research-model operations, laboratory services, discovery capabilities, and the company's presence in China. In 2010, Charles River proposed acquiring WuXi PharmaTech, but withdrew the offer after opposition from several major investors and a negative recommendation from the proxy advisory firm RiskMetrics. Charles River broadened its early-stage discovery platform through the 2014 acquisitions of Argenta and BioFocus, adding integrated in vitro and in vivo capabilities. It then acquired Celsis International in 2015, WIL Research and Blue Stream Laboratories in 2016, Brains On-Line in 2017, KWS BioTest and MPI Research in 2018, and Citoxlab and HemaCare in 2019. The MPI Research transaction, completed in April 2018, significantly increased the company's preclinical research capacity. Citoxlab added capabilities in areas including preclinical testing, while HemaCare strengthened access to human biospecimens and cell-therapy-related services. The company continued its expansion in advanced therapies and biological development. It acquired Cellero in 2020, Distributed Bio and Cognate BioServices in 2021, followed by Retrogenix and Vigene Biosciences in the same year. Cognate and Vigene supported the development and manufacturing of cell and gene therapy products, while Distributed Bio added antibody-discovery technology. In 2022, Charles River announced the acquisition of Explora BioLabs, and in 2023 it announced the acquisition of SAMDI Tech, extending its capabilities in drug-discovery technologies. The company has also addressed animal-welfare concerns through internal programs. In 2002 it launched the Humane Care Imperative, intended to promote awareness, training, and responsibility relating to the care and use of laboratory animals. Nevertheless, its use and supply of research animals have remained subjects of public scrutiny. In 2023, Born Free USA objected to a proposed export of approximately 1,000 endangered juvenile long-tailed macaques to Cambodia for testing. These controversies illustrate the continuing tension between biomedical research requirements, regulatory systems, commercial CRO operations, and animal-welfare campaigns. By 2024, Charles River operated across at least 20 countries and employed more than 20,000 people according to the supplied reference material. The modern company is therefore substantially broader than its original animal-supply business, offering an integrated platform covering discovery, research models, safety assessment, laboratory testing, preclinical development, and support for advanced-therapy manufacturing.
- 2021
Cell and gene therapy capabilities expanded
[1]Acquisitions including Cognate BioServices, Retrogenix, and Vigene Biosciences broadened advanced-therapy discovery and manufacturing support.
- 2018
MPI Research acquired
[1]The company completed its acquisition of MPI Research, strengthening its preclinical research platform.
- 2014
Argenta and BioFocus acquired
[1]The acquisitions expanded Charles River's integrated early-stage discovery capabilities.
- 2010
WuXi PharmaTech acquisition proposal withdrawn
[1]Charles River withdrew its proposed acquisition after investor opposition and an unfavorable proxy-adviser recommendation.
- 2008
National Cancer Institute partnership
[1]The company signed a ten-year contract with the National Cancer Institute and opened a facility in Frederick, Maryland.
- 2003
Merger with Inveresk
[1]Charles River merged with United Kingdom-based Inveresk to expand clinical and preclinical research capabilities.
- 2002
Humane Care Imperative launched
[1]The company introduced an animal-care initiative focused on employee awareness and training.
- 1988
Transgenic research models added
[1]Charles River began producing transgenic mice and rats.
- 1984
Acquired by Bausch & Lomb
[1]Bausch & Lomb acquired Charles River.
- 1981
Genetic monitoring program introduced
[1]The company implemented a commercial comprehensive genetic-monitoring program for research colonies.
Products and positioning
A global, integrated CRO combining research models, discovery science, preclinical development, safety testing, laboratory testing, and selected manufacturing services for pharmaceutical and biotechnology programs.
Laboratory animals and biological research models · 1947
Research models
Charles River supplies and manages research models used in pharmaceutical, biotechnology, academic, and government studies. The offering developed from the company's original laboratory-animal business and includes rodents and other models, associated health controls, colony management, genetic characterization, and preconditioning services intended to provide study-ready animals.
Contract research
Preclinical research
Preclinical services cover pharmacology, toxicology, efficacy, and other in vivo and in vitro studies performed before or alongside human clinical development. These services help sponsors characterize candidate medicines, select development programs, and prepare technical packages for regulatory review.
Toxicology and regulatory support
Safety assessment
The company conducts safety and toxicology work for drugs, biologics, vaccines, and medical devices. Its testing can support dose selection, risk characterization, regulatory submissions, and decisions about whether a candidate should advance into later development.
Laboratory testing · 1990
Microbial and endotoxin testing
Charles River provides microbial, sterility, contamination-control, and endotoxin-testing services for pharmaceutical and biotechnology products. These activities help manufacturers and developers assess product quality and meet requirements associated with regulated production and release testing.
Discovery research · 2014
Drug discovery services
Discovery services include target-related research, screening, in vitro and in vivo biology, antibody discovery, and other early-stage activities. Acquisitions such as BioFocus, Argenta, and Distributed Bio helped build a broader discovery platform linking molecular research with preclinical development.
Advanced-therapy development and manufacturing · 2019
Cell and gene therapy support
Through businesses including Cognate BioServices, HemaCare, Cellero, and Vigene Biosciences, Charles River supports cell- and gene-therapy programs with biological materials, development services, vector-related capabilities, and contract manufacturing support.
Controversies
2023
Protest over proposed macaque export
Born Free USA protested Charles River's plan to export approximately 1,000 endangered juvenile long-tailed macaques to Cambodia for testing. The episode drew attention to the company's role in supplying and using nonhuman primates in biomedical research and to related conservation and animal-welfare questions.
Marketing campaigns
- 2002Humane Care Imperative
Global
Charles River launched an internal animal-welfare initiative intended to raise awareness and train employees regarding the humane care and responsible use of laboratory animals.
Outcome. The initiative became part of the company's stated animal-care and training approach.
Brand decisions
2019
San Diego operations closure and breeding relocationStrategyBackground
The company reviewed its operating footprint for rodent breeding and compound-testing support.
Action taken
Charles River announced that it would close its San Diego operations and move relevant breeding activities to Hollister, California.
Aftermath
The change consolidated the affected rodent-breeding activity at another California location.
2010
Withdrawal of WuXi PharmaTech acquisition proposalM&ABackground
Charles River proposed acquiring China-based CRO WuXi PharmaTech, but several significant investors opposed the transaction and the proxy advisory firm RiskMetrics recommended voting against it.
Action taken
The company withdrew the proposed acquisition.
Aftermath
Charles River continued expanding through smaller and more targeted acquisitions in research models, discovery, laboratory testing, and preclinical services.
Recent events
Charles River completes acquisition of Retrogenix[3]
Charles River completed its acquisition of Retrogenix, a contract research organization providing specialized bioanalytical services.
Charles River completes Cognate BioServices acquisition[4]
Reported:
Charles River Laboratories announced that it completed its previously announced acquisition of Cognate BioServices for approximately $875 million, subject to customary closing adjustments.
Charles River plans to acquire Cognate BioServices[5]
Reported:
Charles River Laboratories announced plans to acquire Cognate BioServices for approximately $875 million in cash. The proposed transaction was expected to close by the end of the first quarter, subject to regulatory requirements and customary closing conditions.
Charles River Laboratories completes acquisition of Distributed Bio[6]
Reported:
Charles River Laboratories completed its acquisition of Distributed Bio for up to $104 million, including $83 million upfront and up to $21 million in milestone payments.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/charles-river-laboratories · Editorial policy · How profiles are compiled